Company news
Clinuvel Pharmaceuticals Limited (ASX:CUV) news
Every Clinuvel Pharmaceuticals Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
CLINUVEL extends Managing Director Employment Agreement
June 28, 2024
afamelanotide in fair-skinned Parkinsons patients
June 17, 2024
CLINUVEL initiates on market share buy-back program
March 14, 2024
New case of SCENESSE efficacy in vitiligo presented at AAD
March 10, 2024
SCENESSE provides photoprotection in variegate porphyria
March 3, 2024
CUV Appendix 4D Half Year Report
February 21, 2024
Appendix 4E and Annual Report to Shareholders 2023
August 29, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2023
Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
October 30, 2022
S&P DJI Announces September 2022 Quarterly Rebalance
September 2, 2022
Appendix 4E and Annual Report 2022
August 30, 2022
Positive Final Results in Stroke Study CUV801
May 3, 2022
ACTH Manufacturing Update
March 16, 2022
afamelanotide in Stroke (AIS) - Positive Preliminary Results
March 14, 2022
CLINUVEL Reports December Half Year Operating Results
February 22, 2022
Appendix 4D Half Year Report
February 22, 2022
Response to ASX Price Query
November 7, 2021
CLINUVEL Delivers Record Revenues and Profit
August 26, 2021
Appendix 4E and Preliminary Financial Report
August 26, 2021
Appendix 4C - quarterly
April 29, 2021
Media Release - CLINUVEL expands DNA Repair Program
March 23, 2021
Appendix 4D Half Yearly Report
February 24, 2021
CLINUVEL Strategic Update - Extended
October 29, 2020
Media Release - CLINUVEL to Trial Innovative Drug in Stroke
October 27, 2020
Australian TGA approves SCENESSE
October 27, 2020
Trading Halt
October 26, 2020
Media Release - First patient dosed in SCENESSE DNA Repair
September 14, 2020
CLINUVEL progresses innovative DNA Repair Program
September 10, 2020
Corporate Presentation - 2020 Full Year Results
August 27, 2020
CLINUVEL Declares Full Year Dividend
August 27, 2020
CLINUVEL Full Year Results
August 27, 2020
CLINUVEL Corporate Update
July 30, 2020
Media Release - SCENESSE to be prescribed in China
April 22, 2020
TGA Priority Registration Pathway for SCENESSE
October 30, 2019
FDA Grants Marketing Approval for SCENESSE
October 8, 2019
CLINUVEL renews CEO Employment Agreement
October 6, 2019
FDA Clarifies SCENESSE PDUFA Date
October 2, 2019
Dividend/Distribution - CUV
August 28, 2019
Appendix 4E and Preliminary Financial Report Reissued
August 28, 2019
CLINUVEL declares Full Year Dividend
August 28, 2019
US FDA extends PDUFA date for SCENESSE
June 2, 2019
US FDA sets PDUFA date for SCENESSE
January 9, 2019
CUV103 Singaporean Phase II vitiligo study results
December 18, 2018
Appeal Upheld Against NICE Recommendation in England
October 9, 2018
S&P DJI Announces September 2018 Quarterly Rebalance
September 6, 2018
US FDA Update
September 4, 2018
CLINUVEL completes SCENESSE FDA Filing
June 25, 2018
NICE maintains position not to recommend SCENESSE
May 22, 2018
CLINUVEL Regulatory Update
May 13, 2018
CLINUVEL TO TAKE 100% OWNERSHIP OF VALLAURIX JOINT VENTURE
May 1, 2018